McGill University researchers have developed an artificial intelligence tool that can detect previously invisible disease markers inside single cells.

In a study published in Nature Communications, the researchers demonstrate how the tool, called DOLPHIN, could one day be used by doctors to catch diseases earlier and guide treatment options.

"This tool has the potential to help doctors match patients with the therapies most likely to work for them, reducing trial-and-error in treatment," said senior author Jun Ding, assistant professor in McGill's Department of Medicine and a junior scientist at the Research Institute of the McGill University Health Centre.

Zooming in on genetic building blocks

Disease markers are often subtle changes in RNA expression that can indicate when a disease is present, how severe it may become or how it might respond to treatment.

Conventional gene-level methods of analysis collapse these markers into a single count per gene, masking critical variation and capturing only the tip of the iceberg, said the researchers.

Now, advances in artificial intelligence have made it possible to capture the fine-grained complexity of single-cell data. DOLPHIN moves beyond gene-level, zooming in to see how genes are spliced together from smaller pieces called exons to provide a clearer view of cell states.

"Genes are not just one block, they're like Lego sets made of many smaller pieces," said first author Kailu Song, a PhD student in McGill's Quantitative Life Sciences program. "By looking at how those pieces are connected, our tool reveals important disease markers that have long been overlooked."

In one test case, DOLPHIN analyzed single-cell data from pancreatic cancer patients and found more than 800 disease markers missed by conventional tools. It was able to distinguish patients with high-risk, aggressive cancers from those with less severe cases, information that would help doctors choose the right treatment path.

A step toward 'virtual cells'

More broadly, the breakthrough lays the foundation for achieving the long-term goal of building digital models of human cells. DOLPHIN generates richer single-cell profiles than conventional methods, enabling virtual simulations of how cells behave and respond to drugs before moving to lab or clinical trials, saving time and money.

The researchers' next step will be to expand the tool's reach from a few datasets to millions of cells, paving the way for more accurate virtual cell models in the future.

About the study

"DOLPHIN advances single-cell transcriptomics beyond gene level by leveraging exon and junction reads" by Kailu Song and Jun Ding et al., was published inNature Communications.

This research was supported the Meakins-Christie Chair in Respiratory Research, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada and the Fonds de recherche du Québec.

Read more …DOLPHIN AI uncovers hundreds of invisible cancer markers

Researchers have discovered a way to make the immune system's T cells significantly more effective at fighting cancer. By blocking a protein called Ant2, they were able to reprogram how these cells consume and generate energy -- essentially rewiring their internal power supply. This shift makes T cells more active, resilient, and better at attacking tumors. The findings open the door to new treatments that could strengthen the body's own immune response, offering a smarter, more targeted approach to cancer therapy.

A new study may pave the way for a new generation of cancer therapies -- by training the body's own immune system to work smarter and hit harder. Led by PhD student Omri Yosef and Prof. Michael Berger from the Faculty of Medicine at Hebrew University, in collaboration with Prof. Magdalena Huber of Philipps University of Marburg and Prof. Eyal Gottlieb of the University of Texas MD Anderson Cancer Center, the international team discovered that fine-tuning immune cells metabolism dramatically improves their ability to destroy cancer.

At the heart of the research is a powerful insight: when T cells -- key players in the immune system -- are forced to rewire how they convert energy, they become significantly more effective at identifying and attacking tumors.

"By disabling Ant2, we triggered a complete shift in how T cells produce and use energy," explains Prof. Berger. "This reprogramming made them significantly better at recognizing and killing cancer cells." In simpler terms, blocking this protein forces the immune cells to adapt their metabolism, turning them into stronger, faster, and more aggressive cancer fighters.

Published in Nature Communications, the study focuses on the mitochondria -- the "metabolic hub" of cells. By deliberately disrupting a specific energy pathway inside T cells, the team essentially rewired the cells' engines, creating a state of heightened readiness and potency. The altered T cells exhibited greater stamina, faster replication, and sharper targeting of cancerous threats.

Perhaps most importantly, the researchers showed that this metabolic rewiring can be triggered not only through genetic modifications but also with drugs -- opening the door for potential clinical applications.

This discovery is part of a growing movement in cancer immunotherapy that focuses not only on guiding the immune system but upgrading its inner machinery. While more studies and clinical trials are needed, the implications of this breakthrough are promising: new treatments that harness the body's own defenses, fine-tuned for peak performance.

"This work highlights how deeply interconnected metabolism and immunity truly are," says Prof. Berger. "By learning how to control the power source of our immune cells, we may be able to unlock therapies that are both more natural and more effective."

Read more …Blocking one protein supercharges the immune system against cancer

More Articles …